We’ve all heard about the importance of aspirin for the prevention of heat disease. But is it really true?
A recent analysis of the published literature of people without heart disease examined a total of 51,342 women and 44,114 men from a range of studies who did not heart disease but had risk factors for heart disease (Berger et al 2006). Daily aspirin in women reduced cardiovascular disease by 12%, which was statistically significant, with a 17% reduction in stroke and no effect on heart attacks or cardiovascular mortality. However for any given woman, the absolute risk reduction, or how much the risk of heart attack was reduced in that individual, was only 0.3% over a six year period. And aspirin increased the risk of major bleeding by 68%. For men there was a 14% reduction of cardiovascular events primarily related to a 32% reduction in heart attacks with no effect on strokes or cardiovascular mortality. That translated into a .37% absolute reduction over a six year period. And men had a 72% increase in major bleeding. Aspirin did not save any lives in men or women. And for every stroke in women or heart attack in men that is prevented by aspirin, there is one major gastrointestinal bleeding event caused by aspirin. Based on this I do not recommend taking aspirin if you don’t have heart disease.
For men with a history of heart disease, taking baby aspirin every day can reduce your risk of death from heart disease by about 17% (ATC 2002). Translated, this means you are reducing your risk by about 1% per year. Although technically the risk of stomach bleeding is outweighed by the heart benefits of aspirin (which can only be shown when large numbers of patients are studied), in terms of what that means to you the differences are not that great. If you don’t mind taking it, you can get some advantage, but not as much as you think. Don’t forget that it is more important to use your energies to walk around the block or do some other activity that can be beneficial.
In patients with strokes or transient ischemic attacks (TIAs) aspirin plus dipyridamole (a blood vessel dilator) was shown to be associated with a 13% rate of cardiovascular event compared to 16% on aspirin alone, a difference that was statistically significant (Esprit 2006).
ATC (2002): Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 324:71-86.
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL (2006): Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. Journal of the American Medical Association 295:306-313.
Esprit (2006): Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. The Lancet 367:1665-1673.